NXL (Nexalin Technology) heads into its May 22 earnings release having shed nearly a third of its value in a single month, now trading at $0.32.
The price collapse is the dominant story. The stock fell 31% over the past month and another 6% on the week, arriving at the print in a state of persistent technical weakness. Peers are sending mixed signals around it — STEX rallied 33% on the week while TMCI gained 19%, making Nexalin's relative underperformance hard to ignore. The borrow market, however, is not flashing distress. Availability is comfortable at roughly 211% of short interest, meaning there are more than two shares available to lend for every share currently borrowed. Cost to borrow has also eased steadily, dropping from above 8% in mid-April to 6.1% now. The lending market has loosened, not tightened.
Short interest is modest and not the driving force here. At 2.9% of free float, with shorts actually declining 2.5% in the latest session and down 24% over the past month, bears have been covering rather than pressing. The ORTEX short score is neutral at 50.6. This is a stock falling on its own weight — not a heavily-shorted name under active assault.
The bull case rests entirely on the gap between current price and analyst aspirations. The sole covering analyst at Maxim Group upgraded to Buy in March 2025 with a $5.00 target. That target is now more than 15 times the current price of $0.32. Given the stock has collapsed from levels well above $2 to $0.32 in the months since that call, this analyst data is materially stale and should be treated with extreme caution — the price-to-target gap is too wide to be reliable. What the data does confirm is a weak EPS surprise track record at the 72nd percentile is one of the few bright spots, while quality and momentum scores remain deeply depressed. Past earnings prints have been punishing: the March 2026 report sent the stock down nearly 8% on the day and 13% over the following five days, while November 2025 produced a similar 8% one-day drop and 14% five-day decline.
The May 22 print tests whether Nexalin can deliver any commercial signal that breaks the pattern of negative post-earnings drift and gives the remaining shareholder base a reason to stop selling.
See the live data behind this article on ORTEX.
Open NXL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
